Human papillomavirus DNA and mRNA positivity of the anal canal in women with lower genital tract HPV lesions: Predictors and clinical implications

Valari, Olga; Koliopoulos, George; Karakitsos, Petros; Valasoulis, George; Founta, Christina; Godevenos, Dimitrios; Dova, Lefkothea; Paschopoulos, Minas; Loufopoulos, Aristotelis; Paraskevaidis, Evangelos

doi:10.1016/j.ygyno.2011.05.033

Cited by 52 publications

(60 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Moreover, all cases with most severe cervical lesions and all cases of anal HPV 16 infections reported any sexual contact with the anus. In contrast with our results, some previous studies did not find any association between anal sex and anal HPV infection in women [6,14]. No history of anal intercourse was shown in 44.5 % (n = 81) out of 182 HIV infected and "high-risk" HIV-negative women with concurrent anal and cervical HPV infection [20].…”

Section: Discussioncontrasting

confidence: 99%

“…Since more than 90 % of anal cancers are caused by high-risk human papillomavirus (HR HPV) infection [9], possible reasons for the greater risk in women include history of cervical intraepithelial neoplasia (CIN) and cervical cancer [10][11][12]. The only two studies dealing with women with lower genital tract intraepithelial lesions or cancers which also looked at anal HPV showed 45 -51 % HPV prevalence in this group [13,14]. In contrast, a large study on the prevalence of anal HPV infection in a healthy population demonstrated just 13 % (178/1363) of cases with concurrent anal and cervical HPV infection [15].…”

mentioning

confidence: 99%

See 1 more Smart Citation

Impact of risk factors on prevalence of anal HPV infection in women with simultaneous cervical lesion

Sláma¹,

Sehnal²,

Dušek³

et al. 2015

neo

View full text Add to dashboard Cite

The aim of our study was to determine the risk factors associated with anal HPV infection in HIV-negative women with high-grade cervical lesion. The study group included 172 "high-risk" women who underwent conization for high-grade cervical intraepithelial lesion or microinvasive cervical cancer (CIN 2+). The control group consisted of 100 "low-risk" women with non-neoplastic gynecologic diseases. All participants completed a questionnaire detailing medical history and sexual risk factors and were subjected to anal and cervical HPV genotyping. Concurrent cervical and anal HPV infections were detected in 42.4% (73/172) women of the study group, and in 8.0% (8/100) of women in the control group, respectively. The subgroup with concurrent HPV infections (n=73) dominated women with CIN 3 and microinvasive cancer and anal HPV 16 infections (n=53). Women with concurrent infections more frequently reported any type of sexual contact with the anus including non-penetrative anal sex (OR 2.62, p=0.008). Reporting >5 lifetime sexual partners (OR 2.43, p=0.041), smoking > 60 cigarettes per week (OR 2.33, p=0.048), and a history of penetrative anal intercourse (OR 3.87, p=0.002) were observed as the significant risk factors in women with multiple concurrent HPV infections. Our data support anal HPV testing and anal Pap smear screening in all women with severe cervical lesions caused by HPV 16 and a history of any sexual contact with the anus, heavy smoking and/or more than 5 lifetime sexual partners. Key words: anal cancer, cervical intraepithelial neoplasia, HPV, risk factorAnal cancer is an uncommon disease, but its incidence has grown during the last decades in most developed countries [1]. The population at the highest risk of developing anal cancer includes HIV-infected subjects, males who have sex with males and transplant recipients [2][3][4][5][6]. Despite this fact, a still significant proportion of anal cancers are detected in generally healthy and HIV-negative subjects. Moreover, anal cancers are more frequently detected in women than in men [7]. In the U.S., invasive anal squamous cell carcinoma rates increased among females by 1.7 % per year between 1973 and 2005 [1]. In 2012 there were an estimated 6230 new cases of anal cancer in the U.S., with 3980 (63.9 %) cases occurring in women and only 2250 (36.1 %) cases in men [8]. Similarly, in the Czech Republic the prevalence of anal cancer is constantly higher among women than in men. In 2010 there were 129 new cases of anal cancer, with 85 (65.9 %) cases in women and 44 (34.1 %) cases in men.This gender difference is not clearly explained. Since more than 90 % of anal cancers are caused by high-risk human papillomavirus (HR HPV) infection [9], possible reasons for the greater risk in women include history of cervical intraepithelial neoplasia (CIN) and cervical cancer [10][11][12]. The only two studies dealing with women with lower genital tract intraepithelial lesions or cancers which also looked at anal HPV showed 45 -51 % HPV prevalence in this group [13,14]. ...

show abstract

Section: Discussioncontrasting

confidence: 99%

mentioning

confidence: 99%

Impact of risk factors on prevalence of anal HPV infection in women with simultaneous cervical lesion

Sláma¹,

Sehnal²,

Dušek³

et al. 2015

neo

View full text Add to dashboard Cite

show abstract

“…Three of them (the 16 cases mentioned above) exhibited HSILs in the biopsy, five had LSILs, five had unaltered HRA images so biopsy was not necessary, and there were two negative smears for mRNA E6/E7 presenting LSILs in the biopsy. Valari et al (2011) studied 235 HIV-women forwarded for colposcopy owing to cytological alterations, and found HR-HPV in the AC in 31% of patients, but only 8% of those exhibited mRNA E6/E7 expression. In our study, the respective findings were 38.9% (16/42) and 33.33% (14/42), demonstrating the importance of HPV infection as a risk factor for positive E6/E7 mRNA expression.…”

mentioning

confidence: 99%

HPV infection-associated anogenital cyto-colpo-histological findings and molecular typing in HIV-positive women

et al. 2015

View full text Add to dashboard Cite

ABSTRACT. HIV and human papillomavirus (HPV) coinfection is increasing, especially in the anal canal (AC) and cervico-vaginal regions.We identified anal epithelium abnormalities related to high-risk HPV (HR-HPV) lesions in the lower genital tracts (LGTs) of HIV-positive women, described the HPV genotypes identified, and assessed the expression of E6/E7 oncogenes in coinfected patients. Ninety-eight women were enrolled in groups combining HIV status and presence or absence of HPV in the LGT. Anal and cervical smears were collected for cytology and HR-HPV assays using Cobas ® and/ or PapilloCheck ® . Samples with highly oncogenic HPV genotypes were confirmed by NucliSENS EasyQ ® . Forty-two HIV-positive (25-52; mean age 39.5) and 56 HIV-negative (18-58; mean age 35.7) patients were included. E2 and C1 groups presented AC alterations (P = 0.002); altered images HPV-associated anogenital cytology in HIV-positive women for high-resolution anoscopy were higher in E1 and C2 (P < 0.001). Of the 29 women with alterations, 41.38% were HIV-negative and 58.62% were HIV-positive (P < 0.001). HIV-positive patients accounted for 29% of the anal high-grade squamous intraepithelial lesions (P = 0.015). The Cobas ® positive result frequency was higher in three AC groups than in the other groups. There was variation in the number of HPV types in the cervicovaginal samples among the study groups (P < 0.001). Anal cytology and anoscopy showed more altered findings in HIV-positive patients with HPV in the LGT. HR-HPV anal infections by various genotypes are common and are associated with cervical infections in HIV-positive patients. E6/E7 expression is apparently more common in the AC of HIV-positive women.

show abstract

“…Пациентки с наличием ВПЧ высокого риска и диспла-зией шейки матки подвержены риску развития анальной интраэпителиальной неоплазии и АР [24,25]. Женщины с персистенцией ВПЧ-инфекции или наличием диспла-зии тяжелой степени и сопутствующей ВПЧ-инфекции анальной области относятся к группе повышенного риска развития AIN [24,26].…”

unclassified

“…Женщины с персистенцией ВПЧ-инфекции или наличием диспла-зии тяжелой степени и сопутствующей ВПЧ-инфекции анальной области относятся к группе повышенного риска развития AIN [24,26]. ВПЧ высокого онкогенного риска выявлены в 91% случаев у пациенток с РШМ и 91% у жен-щин с АР [27].…”

unclassified

Human papillomavirus-associated anal and cervical neoplasia: evaluation of vaccino-prophylaxis programs

Nazarova¹,

Прилепская²

2018

Med. sov.

View full text Add to dashboard Cite

П апилломавирусная инфекция (ПВИ) является основным этиологическим фактором развития предрака и рака аногенитальной области. Так, высокоонкогенные типы вируса папилломы человека (ВПЧ) являются причиной 91% случаев рака шейки матки (РШМ) и ануса, 75% -влагалища, 69% -вульвы [1][2][3][4][5][6]. По результатам исследования, которым было охвачено 100% населения США (2004)(2005)(2006)(2007)(2008), было выявлено, что за 1 год регистрируется более 33 300 случаев ВПЧ-ассоциированного рака. Ежегодно 21 300 случаев ВПЧ-ассоциированного рака диагностируется среди женщин, 12 100 -среди мужчин. РШМ является наиболее распро-страненной формой ВПЧ-ассоциированного рака среди женщин. По данным Международного агентства по изуче-нию рака, ежегодно в мире регистрируются 470 000 новых случаев РШМ, половина из которых заканчиваются Keywords : anal intraepithelial neoplasia, cervical intraepithelial neoplasia, human papilloma virus, cervical cancer, anal cancer, HPV and cervical, vaginal, vulva and anus vaccines.

show abstract

Human papillomavirus DNA and mRNA positivity of the anal canal in women with lower genital tract HPV lesions: Predictors and clinical implications

Cited by 52 publications

References 15 publications

Impact of risk factors on prevalence of anal HPV infection in women with simultaneous cervical lesion

Impact of risk factors on prevalence of anal HPV infection in women with simultaneous cervical lesion

HPV infection-associated anogenital cyto-colpo-histological findings and molecular typing in HIV-positive women

Human papillomavirus-associated anal and cervical neoplasia: evaluation of vaccino-prophylaxis programs

Contact Info

Product

Resources

About